Anat Polyachenko

Anat Polyachenko

Baker & McKenzie LLP


Anat Polyachenko is an associate in the Corporate & Securities Practice Group and the Life Sciences Industry Group, based in the New York office.

Practice Focus

Anat represents emerging to mature life sciences companies, as well as private equity and venture capital funds. She advises on a broad range of corporate and transactional affairs, including licensing transactions, collaboration agreements, strategic alliances, joint ventures, cross-border mergers and acquisitions and equity investments. Anat also handles contractual arrangements for drug discovery, research, development, manufacturing and supply, and commercialization of new products.

Representative Legal Matters

Licensing and Collaboration Agreements

  • H. Lundbeck A/S in its collaboration with Rgenta Therapeutics to discover small molecules targeting RNA regulation and splicing of disease-causing genes.

  • Astellas in its license agreement with ExCellThera for the in vitro use of certain molecules in the field of pluripotent stem cells (PSCs) and PSC-derived cells.

  • H. Lundbeck A/S in the licensing to Denovo Biopharma of global rights to idalopirdine (an oral 5-HT6 antagonist) for Alzheimer's Disease, schizophrenia and other indications, subject to options for Lundbeck to re-acquire such rights with the parties sharing China rights.

Mergers and Acquisitions

  • Bayer AG in its acquisition of drug discovery company Vividion Therapeutics for USD 1.5 billion upfront and up to USD 500 million in success-based milestone payments.

  • Kite in the sale to BioNTech of their neoantigen TCR cell therapy R&D platform and manufacturing facility.

Professional Associations and Memberships

  • Certified Information Privacy Professional US Private Sector (CIPP/US)
  • New York State Bar Association - Member


  • New York~United States (2021)
  • Israel (2018)


  • Duke University School of Law (LLM) (2020)
  • Tel Aviv University (2017)


  • English
  • Hebrew
  • Russian